- Conditions
- Ovarian Cancer
- Interventions
- Trastuzumab Deruxtecan, Bevacizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 33
- States / cities
- Burbank, California • La Jolla, California • Palo Alto, California + 26 more
Location Directory
Clinical trials in Indianapolis, Indiana
This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8604
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 97–108 of 8,604 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Stage IV Lung Cancer, Stage IV Gastrointestinal Cancer
- Interventions
- Spiritual Care, Informational Support
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Indianapolis, Indiana • Lafayette, Indiana
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more
- Conditions
- Androgenetic Alopecia
- Interventions
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Drug
- Lead sponsor
- Pelage Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Hot Springs, Arkansas + 50 more
- Conditions
- Peanut Allergy
- Interventions
- DBV712 250 mcg
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
- Conditions
- Childhood Cancer
- Interventions
- SurvivorLink
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 9 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 226
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
- Drug
- Lead sponsor
- Expedition Therapeutics, Inc
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Encino, California • Northridge, California + 26 more
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Advanced Solid Tumors
- Interventions
- LY4337713
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 20
- States / cities
- Newport Beach, California • Stanford, California • Miami, Florida + 14 more
- Conditions
- Pregnancy
- Interventions
- Cervical Ripening with a double balloon catheter only, Cervical ripening with a double balloon catheter plus misoprostol, Usual-care control group
- Device · Combination Product
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Carcinoma
- Interventions
- NearWave monitoring
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more